Metallo-antiviral aspirants: Answer to the upcoming virus outbreak.

In light of the current SARS-CoV-2 outbreak, about one million research papers (articles, reviews, communications, etc.) were published in the last one and a half years. It was also noticed that in the past few years; infectious diseases, mainly those of viral origin, burdened the public health systems worldwide. The current wave of the Covid-19 pandemic has unmasked critical demand for compounds that can be swiftly mobilized for the treatment of re-emerging or emerging viral infections. With the potential chemical and structural characteristics of organic motifs, the coordination compounds might be a promising and flexible option for drug development. Their therapeutic consequence may be tuned by varying metal nature and its oxidation number, ligands characteristics, and stereochemistry of the species formed. The emerging successes of cisplatin in cancer chemotherapy inspire researchers to make new efforts for studying metallodrugs as antivirals. Metal-based compounds have immense therapeutic potential in terms of structural diversity and possible mechanisms of action; therefore, they might offer an excellent opportunity to achieve new antivirals. This review is an attempt to summarize the current status of antiviral therapies against SARS-CoV-2 from the available literature sources, discuss the specific challenges and solutions in the development of metal-based antivirals, and also talk about the possibility to accelerate discovery efforts in this direction.

Identification of pharmacophore in bioactive metal complexes: Synthesis, spectroscopic characterization and application.

Bacteria are amongst the most adaptable organisms on the Earth. The year 2010 was always remarkable for the article published in Lancet Infection Disease by Kumarasamy et al. and the enzyme NDM-1 which makes bacteria resist designed to kill them. Four rhodium(III) chloride complexes with Gatifloxacin have been prepared and characterized by elemental analyses, molar conductance measurements, FTIR, FAB-MS, TGA, (1)H NMR and electronic spectral studies. The general formula for complexes are [X](+)fac-[RhCl(3)(L)(GT)](-); where L = H(2)O, Dimethylsulfoxide (DMSO), Tetramethylenesulfoxide (TMSO); GT = Gatifloxacin and X = Na or [H(DMSO)(2)]. All complexes are found to possess prominent antibacterial activity against pathogenic Escherichia coli and Mycobacterium tuberculosis in comparison to Gatifloxacin.

Synthesis, Spectroscopic Characterization and Antibacterial Activity of some Chloro Dimethylsulphoxide/ Tetramethylenesulphoxide Ruthenium (II)/(III) Complexes with 1, 2, 3-Benzotriazole.

Synthesis and characterization of seven ruthenium (II) and ruthenium (III) chloro sulphoxide complexes with 1, 2, 3-benzotriazole are reported. Three different formulations exist: [cis, fac-RuCl2(so)3(btz)]; [trans-RuCl2(so)3(btz)] and [trans-RuCl4(so)(btz)]-[X]+; where so=dimethylsulphoxide/ tetramethylenesulphoxide; btz = 1, 2, 3-benzotriazole and [X]+ = [(btz)H]+ or Na+. These complexes were characterized by elemental analysis, conductivity measurements, magnetic susceptibility, FT-IR, 1H-NMR, 13C1H-NMR and electronic spectroscopy. Complexes were screened for their antibacterial activity and found more potent than 1, 2, 3-benzotriazole ligand and precursor ruthenium compounds against gram-negative bacteria Escherichia coli. All the samples were compared with antibiotic Chloramphenicol for reference.